<DOC>
	<DOCNO>NCT01862120</DOCNO>
	<brief_summary>Human recombinant interleukin-2 ( rhIL-2 ) biological signal protein play key role regulation immune system . At high dos , rhIL-2 activates immune effector T cell ( TEFFS ) low dose rhIL-2 induces activate regulatory T cell ( TREGS ) , population immune cell control immune Teff response . In patient Type 1 Diabetes ( T1D ) , TREGS fail control autoimmune destruction TEFFS pancreatic beta-cells produce insulin . The investigator recently show rhIL-2 low dose well tolerated patient autoimmune disease adult establish T1D , induce TREGS without effect TEFFS . The investigator aim use rhIL-2 low dose induce/stimulate TREGS young recently diagnose T1D patient . This study investigate dose effect relationship low dose rhIL-2 TREG induction optimize risk benefit ratio treatment T1D . Through Treg induction , investigator aim protect remaining/regenerating pancreatic β-cells autoimmune destruction , thus improve even cure T1D .</brief_summary>
	<brief_title>Dose Finding Study Il-2 Ultra-low Dose Children With Recently Diagnosed Type 1 Diabetes</brief_title>
	<detailed_description>Main objective : Define low dose rhIL-2 inducing TREGS child recently diagnose type 1 diabetes . Conduct study : Three dos study versus placebo parallel group six patient . Each dose placebo study accord three period treatment : 1 . Induction TREGS follow cure 5 day repeat daily administration [ day 1 - day 5 ] . 2 . Maintenance TREGS follow repeat administration every two week one year [ day 15 - day 337 ] . At treatment period , Treg response tolerance evaluate . In addition , overall response T1D parameter assess throughout study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion criterion : Age [ 713 ] year girls [ 714 ] year boys With T1D diagnosis ( ADA ) Treated insulin ≤ 3 month , With least one autoantibody among : antiinsulin , antiGAD , antiIA2 , antiZnT8 ; No clinically relevant abnormal finding haematology , biochemistry , liver kidney function Informed consent sign patient , parent , investigator intervention necessary trial . Exclusion criterion : Contraindications IL2 : Hyper sensibility IL2 excipients , Severe cardiopathy Previous organ allograft Ongoing infection require antibiotherapy , O2 Saturation ≤ 90 % Severe impairment vital organ Documented history autoimmune disease ( except autoantibody , IAA , GADA , IA2A , antiZnT8A , stable thyroiditis normal TSH ( &lt; 10 mUI/L ) , T3 , T4 level . Diabetes onset characteristic include : Continuous nocturnal polyuria ≥ 3 month ; Inaugural acidosis ( venous Ph &lt; 7.25 ) ; HbA1c diagnostic ≥ 13 % ; Weight loss ≥ 10 % diagnosis ; Positive autoantibodies 21hydroxylase Stage 2 obesity Non authorize concomitant treatment : immunomodulators , cytotoxic drug , drug modify plasma glycemia vaccination ≤ 4 week life vaccin Positive serology ( IgM ) EpsteinBarr virus ( EBV ) and/or cytomegalovirus ( CMV ) , reflect acute infection . Participation another clinical investigation previous 3 month No affiliation National Health Insurance</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Recently diagnose</keyword>
	<keyword>Regulatory T Cells</keyword>
	<keyword>Tolerance Induction</keyword>
	<keyword>Paediatrics</keyword>
	<keyword>Low dose</keyword>
	<keyword>IL-2</keyword>
</DOC>